Vicore Pharma strengthens team with two key hires to support focus on rare lung disease
September 17, 2018 - Vicore Pharma (publ) announced today it has appointed Rohit Batta as Chief Medical Officer effective November 26 and Göran Tornling as Senior Medical Advisor starting September 17. Dr. Batta will report to the CEO and join the Vicore Pharma Executive Team. Both recruitments are important to bolster Vicore’s medical competencies in the pulmonary rare disease space.
Dr. Rohit Batta has 18 years of experience as a medical doctor with an extensive background, leading medical and clinical development teams whilst developing drugs for rare diseases. His previous roles include Senior Director of Cell and Gene Therapy at GlaxoSmithKline (GSK) with responsibility for leading the clinical development team and defining the clinical strategy for haemoglobinopathy gene therapy medicines. He also led the global medical and late stage clinical development teams to launch the world’s first gene therapy for patients with a pediatric rare disease.
Dr. Batta holds an MBBS from Kings College School of Medicine and is a member to the Royal College of General Practitioners and to the Faculty of Pharmaceutical Medicine.
Dr. Göran Tornling has almost four decades’ experience as a physician specializing in respiratory medicine. His previous roles include Executive Director Clinical Science and Strategy (Respiratory) at AstraZeneca R&D with responsibility for developing clinical strategies, including an IPF program which is Vicore’s main indication. He was EVP and Head Research and Development at Orexo, responsible for research and preclinical development and pharmaceutical innovation and development.
Dr. Tornling is a graduate of Sweden’s Royal Institute of Technology and Karolinska Institutet and is a certified specialist in respiratory and occupational medicine.
“Batta and Tornling are top-notch minds in their space and are passionate about helping people in need – exactly the type of capabilities Vicore needs to form its world-class medical team and continue the development momentum in our clinical programs”, said Vicore Pharma’s CEO, Dr. Carl-Johan Dalsgaard.
For further information, please contact:
Dr. Carl-Johan Dalsgaard, CEO: +46 709 759 863, carl-johan.dalsgaard@vicorepharma.com
About Vicore Pharma Holding AB (publ)
Vicore Pharma AB is focused on the development of drugs for the treatment of interstitial lung diseases. The company’s two major development programs, VP01 (C21) and VP02 (IMiD), act through the AT2 receptor and is an immunomodulatory drug substance class being developed for local treatment, respectively. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis (IPF), a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. VP02 has in earlier experiments shown an effect in for example idiopathic pulmonary fibrosis with another administration form which, however, has limited its continued development. VP02 is being developed for local treatment in order to overcome such shortcomings. The company is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (ticker: VICO) is listed on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com
Tags: